Ipamorelin 10mg

Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. Activation at the pituitary drives release of stored growth hormone in a pulsatile fashion. Because it acts as a secretagogue — prompting release of the body's own GH rather than supplying GH directly — it is studied as a tool compound for probing the GH axis. Its defining characteristic in the literature is selectivity. In the foundational characterization by Raun and colleagues (1998), Ipamorelin released growth hormone with a potency comparable to GHRP-6, but — unlike GHRP-6 and GHRP-2 — did so without significant elevation of ACTH or cortisol, and without meaningfully affecting prolactin, FSH, LH, or TSH. This "clean" GH-selective profile is the reason it is often referenced as the first selective GH secretagogue. Beyond the GH axis, Ipamorelin has been examined in gastrointestinal-motility research as a ghrelin-mimetic, including rodent models of postoperative ileus (gastric dysmotility). Read the full Ipamorelin Research Guide →

A common reason Ipamorelin appears in comparative research is its narrow hormonal footprint relative to earlier growth hormone-releasing peptides: GHRP-6: reported in the source literature to release GH, with concurrent orexigenic activity and elevation of cortisol/ACTH. GHRP-2 (pralmorelin): potent GH release, but with more pronounced ACTH, cortisol, and prolactin effects. Ipamorelin: GH release comparable to GHRP-6 in the original work, with ACTH and cortisol reported at or near baseline. It is frequently studied alongside the GHRH analog CJC-1295, because a GHRH analog plus a GHS-R agonist act on two complementary pathways of the GH axis.

Ipamorelin was originally developed by Novo Nordisk (as NNC 26-0161) and later investigated by Helsinn Therapeutics in Phase II trials for postoperative ileus. That clinical program was discontinued for lack of efficacy on its primary endpoint, and Ipamorelin has never been approved as a therapeutic drug. Most of the human GH-release data comes from small early-phase pharmacology studies rather than large controlled trials. We flag this deliberately: the selectivity findings are well characterized in preclinical and early clinical work, but Ipamorelin remains an investigational research compound, not an approved medicine.

Every batch of Ipamorelin is independently tested using HPLC-UV for purity verification and mass spectrometry for molecular identity confirmation. The batch-specific Certificate of Analysis (COA) is published on our Lab Results page, and the current lot ip10-0626-01 was assayed by Janoshik Analytical (report #169441, June 2026) at 99.673% purity, as listed in the specifications table above. Testides (Toronto) confirmation pending. New to reading a COA? See our guide on how to read a peptide certificate of analysis.

Ipamorelin is supplied as a lyophilized (freeze-dried) powder for maximum stability. Lyophilized (unopened): Store at -20°C long-term or 2-8°C short-term Light: Protect from direct light at all times Temperature cycling: Keep the sealed vial at a steady temperature and limit warm/cold swings. A manual-defrost freezer, or the back of a frost-free unit, holds a more stable temperature than a door shelf. Condensation: Let a cold, still-sealed vial come up to room temperature before the seal is broken, so atmospheric moisture does not condense onto the powder.

Shipping is free on every order, Canada-wide, with no minimum order value, and every parcel is tracked. All orders ship from British Columbia, Canada. Processing: Dispatched within 48 hours (Mon-Fri) Delivery: Typically 2-8 business days anywhere in Canada Tracking: A tracking number is emailed as soon as your order ships All research compounds are packaged in temperature-stable, tamper-evident materials. Vials are individually wrapped in discreet, unbranded packaging. View full shipping policy →

If your order arrives damaged or does not arrive within the expected timeframe, contact us at info@thepeptide.ca within 48 hours of the expected delivery date. Include your order number and photos of any damage. Due to the nature of research compounds, we cannot accept returns on opened or prepared products. Sealed, unopened vials may be eligible for exchange within 14 days of delivery. View full refund policy →